AI Verdict
LII has stronger fundamentals based on our AI analysis.
LIMNW vs LII Fundamental Comparison
| Metric | LIMNW | LII |
|---|---|---|
| Revenue | N/A | $5.2B |
| Net Income | $-10.2M | $805.8M |
| Net Margin | N/A | 15.5% |
| ROE | N/A | 69.3% |
| ROA | -1,990.4% | 19.7% |
| Current Ratio | 0.05x | 1.60x |
| Debt/Equity | N/A | 0.98x |
| EPS | $-0.43 | $22.79 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
LIMNW vs LII: Frequently Asked Questions
Is LIMNW or LII a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), LII has stronger fundamentals. LIMNW is rated STRONG SELL (95% confidence) while LII is rated HOLD (72% confidence). This is not investment advice.
How does LIMNW compare to LII fundamentally?
Liminatus Pharma, Inc. has ROE of N/A vs LENNOX INTERNATIONAL INC's 69.3%. Net margins are N/A vs 15.5% respectively.
Which stock pays higher dividends, LIMNW or LII?
LIMNW has a dividend yield of N/A or no dividend while LII has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in LIMNW or LII for long term?
For long-term investing, consider that LIMNW has STRONG SELL rating with 95% confidence, while LII has HOLD rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about LIMNW vs LII?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For LIMNW vs LII, the AI consensus favors LII based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.